Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK+ Non-Small-Cell Lung Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT06586801
What this trial is testing

The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China

Who this might be right for
Non-small Cell Lung Cancer
Shanghai East Hospital 800
Testing effectiveness (Phase 2)Looking for participantsNCT05456256
What this trial is testing

LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

Who this might be right for
Adenocarcinoma of LungCarcinoma, Non-Small-Cell Lung
Lantern Pharma Inc. 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06682884
What this trial is testing

Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer

Who this might be right for
Neoadjuvant Non-Small Cell Lung Cancer
Peking University People's Hospital 25
Not applicableNot Yet RecruitingNCT06652555
What this trial is testing

The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study

Who this might be right for
ALKNSCLC
Shanghai Pulmonary Hospital, Shanghai, China 100
Not applicableLooking for participantsNCT07633626
What this trial is testing

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

Who this might be right for
Advanced ALK/ROS1-positive NSCLCCarcinoma, Non-Small-Cell Lung (NSCLC)Lung Adenocarcinoma+3 more
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo 24
Large-scale testing (Phase 3)Ended earlyNCT02775006
What this trial is testing

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

Who this might be right for
Carcinoma, Non-small Cell Lung
The Netherlands Cancer Institute 45
Not applicableUnknownNCT03647111
What this trial is testing

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 120
Not applicableNo Longer AvailableNCT02784158
What this trial is testing

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerLung CancerAdvanced Malignancies+1 more
Ariad Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT04323436
What this trial is testing

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 31
Not applicableStudy completedNCT01300429
What this trial is testing

Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT06007937
What this trial is testing

Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Who this might be right for
Non Small Cell Lung CancerMetastaticRecurrent
Memorial Sloan Kettering Cancer Center 9
Testing effectiveness (Phase 2)Study completedNCT03088930
What this trial is testing

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Nonsmall Cell
University of Colorado, Denver 3
Not applicableStudy completedNCT02304406
What this trial is testing

Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa

Who this might be right for
Non-small Cell Lung Cancer
Pfizer 449
Early research (Phase 1)Study completedNCT00585195
What this trial is testing

Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Who this might be right for
Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more
Pfizer 596
Testing effectiveness (Phase 2)Active Not RecruitingNCT05845671
What this trial is testing

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Who this might be right for
Lung CancerNon Small Cell Lung Cancer
University of Colorado, Denver 12
Not applicableAvailableNCT06834074
What this trial is testing

Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

Who this might be right for
Non Small Cell Lung CancerALK-positive Non-small Cell Lung Cancer (NSCLC)
Nuvalent Inc.
Testing effectiveness (Phase 2)Study completedNCT01945021
What this trial is testing

Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerROS1 Proto OncogeneCrizotinib
Pfizer 129
Testing effectiveness (Phase 2)Looking for participantsNCT07360743
What this trial is testing

Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels

Who this might be right for
Non Small Cell Lung Cancer (Squamous or Non Squamous)
UNICANCER 275
Not applicableStudy completedNCT02042105
What this trial is testing

A Prospective Epidemiologic Study of ALK-Positive NSCLC in China

Who this might be right for
Non-small-cell Lung Cancer
Guangdong Association of Clinical Trials 3,649
Large-scale testing (Phase 3)Study completedNCT02352948
What this trial is testing

A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Who this might be right for
Non - Small Cell Lung Cancer NSCLC
AstraZeneca 597
Next Page